The Bexion Story
Bexion Pharmaceuticals completes Phase 1a of their First Clinical Trial. Bexion receives the “Emerging Business” Award from LEAD Magazine and the Business Impact Award (Micro Business) from the Northern Kentucky Chamber of Commerce.
Bexion Pharmaceuticals Receives FDA Clearance for the First Clinical Trial Using BXQ-350 to Dose Patients with Cancer.
Bexion was awarded “Medical Professional Award” at the American Cancer Society’s Annual Strider’s Ball.
Bexion Pharmaceuticals Receives Orphan Drug Designation for Saposin C, the Active Ingredient in BXQ-350 for Glioblastoma Multiforme from FDA. Bexion wins a Tibbett’s Award by the Small Business Administration for exemplifying the very best in innovation.
Bexion prepares IND for Phase 1
Bexion wins prestigious $2.9MM NCI Bridge Award for Phase 1 in brain cancer
BXQ-350 in IND-enabling studies in preparation for Phase 1 clinical studies
Bexion held a very successful Pre-IND meeting with the FDA. Bexion plans to complete pre-tox animal studies and file IND with the FDA
Bexion wins partnership with Nanotechnology Characterization Lab of NCI, and also $1.5MM NIH grant for brain cancer.
Bexion wins grants to study brain, pancreatic and prostate cancer.
Bexion obtains Series A investment to fund efforts up to Phase 1 clinical study.
Ray Takigiku, Ph.D. co-founds Bexion Pharmaceuticals; licenses anti-cancer technology from CCHMC
Dr. Qi receives a small grant to study the protein on childhood cancer.
Dr. Qi discovers that a protein involved in the inherited disease has anti-cancer properties.
Xiaoyang Qi, Ph.D., a geneticist, joins CCHMC to find a cure for a rare inherited disease.